Structure‐Based Drug Design of Novel Heterocyclic Scaffolds as TgCDPK1 Inhibitors
- 8 August 2025
- journal article
- Published by Wiley in ChemMedChem
- p. e202500440
Abstract
Toxoplasmosis is caused by the protozoan parasite Toxoplasma gondii and poses grave health concern for immunocompromised patients. T. gondii has a family of calcium dependent protein kinases (CDPKs) that control a variety of critical processes. Among these, TgCDPK1 is required for parasite motility, cell invasion, and egress and hence is essential both for in vitro growth of T. gondii and to cause infections in animals. Using existing X‐ray cocrystal structures of pyrazolopyrimidine (PP) inhibitors bound to TgCDPK1, six new chemical series of inhibitors are rationally designed. The synthesis of analogs based on the most promising novel series is pursued, which resulted in potent TgCDPK1 inhibitors that effectively block parasite growth in cells. The resulting lead compounds 44 and 45 belonging to the imidazopyrazine chemical series demonstrate the promising potential of this new class of inhibitors for the treatment and possible cure of the Toxoplasmosis.Keywords
This publication has 34 references indexed in Scilit:
- Efficacy of the bumped kinase inhibitor BKI-1708 against the cyst-forming apicomplexan parasites Toxoplasma gondii and Neospora caninum in vitro and in experimentally infected miceInternational Journal for Parasitology: Drugs and Drug Resistance, 2024
- Pyridopyrimidinones as a new chemotype of calcium dependent protein kinase 1 (CDPK1) inhibitors for CryptosporidiumMolecular and Biochemical Parasitology, 2024
- Control of human toxoplasmosisInternational Journal for Parasitology, 2021
- Optimizing Pyrazolopyrimidine Inhibitors of Calcium Dependent Protein Kinase 1 for Treatment of Acute and Chronic ToxoplasmosisJournal of Medicinal Chemistry, 2020
- Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic ReviewDrugs in R&D, 2017
- Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritisBioorganic & Medicinal Chemistry Letters, 2017
- Imidazo[1,5-a]pyrazines: Orally efficacious inhibitors of mTORC1 and mTORC2Bioorganic & Medicinal Chemistry Letters, 2011
- 1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitorsBioorganic & Medicinal Chemistry Letters, 2007
- Toxoplasma gondii: the model apicomplexanInternational Journal for Parasitology, 2004
- Toxoplasma Invasion of Mammalian Cells Is Powered by the Actin Cytoskeleton of the ParasiteCell, 1996